Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809562 | 0.99 | SIGMAR1 (0.44) | SIGMAR1L3MBTL1 | |
| SCHEMBL16809543 | 0.89 | SIGMAR1 (0.42) | SIGMAR1 | |
| SCHEMBL16809663 | 0.87 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL16809545 | 0.83 | SIGMAR1 (0.43) | SIGMAR1 | |
| SCHEMBL19894332 | 0.80 | CA2 (0.36) | SIGMAR1 | |
| SCHEMBL19894334 | 0.80 | CA2 (0.36) | SIGMAR1 | |
| SCHEMBL16809548 | 0.79 | SIGMAR1 (0.41) | SIGMAR1L3MBTL1 | |
| SCHEMBL18169320 | 0.78 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL18169306 | 0.78 | CA2 (0.41) | — | |
| SCHEMBL16809680 | 0.78 | SIGMAR1 (0.42) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-09-25 | — | — | US | disclosed |
| EP-3079687-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO LTD (KR) | 2018-02-28 | — | — | EP | disclosed |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| WO-2015088272-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015088272-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, SULT1A1, TRPV1 | SIGMAR1 322/4885L3MBTL1 4778/4885 |
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | SULT2A1, SULT1A1, TRPV1 | SIGMAR1 322/4885L3MBTL1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.